Wargacki Stephen 4
4 · Aquestive Therapeutics, Inc. · Filed Aug 9, 2023
Insider Transaction Report
Form 4
Wargacki Stephen
Chief Science Officer
Transactions
- Award
Performance Stock Units
2023-08-09+67,500→ 67,500 totalExp: 2026-05-05→ Common Stock (67,500 underlying)
Footnotes (1)
- [F1]Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.